AuditLine › HHS OIG › Centers for Medicare and Medicaid Services
HHS OIG recommendation 19-A-02-144.02
We recommend the State agency work with CMS to determine whether the other pharmacy and physician-administered drugs were eligible for rebates and,…
The recommendation, in the publisher's words
We recommend the State agency work with CMS to determine whether the other pharmacy and physician-administered drugs were eligible for rebates and, if so, upon receipt of the rebates, refund up to an estimated $47,426,944 (Federal share) our audit period and $119,561,574 (Federal share) for the nearly 4-year period before our audit period.
- Responsible agency
- Centers for Medicare and Medicaid Services
- Issued
- August 30, 2019
- Report
- New Jersey Did Not Bill Manufacturers for Tens of Millions of Dollars in Rebates for Drugs Dispensed to Enrollees of Medicaid Managed-Care Organizations (A-02-16-01011) · find it at HHS OIG
- Kind of report
- Audit
- Agency response
- Concur (as recorded by the publisher)
- Last update received
- October 5, 2026
- Next update expected
- April 13, 2027 (publisher's date)
- Publisher topics
- Managed Care, Prescription Drug
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Dated history
- Issued by HHS OIG. (publisher's date)
- First recorded by AuditLine. (start of AuditLine's own history for this record)
- Last update received changed from “April 17, 2026” to “October 5, 2026”. (observed by AuditLine in the publisher's file)
Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.
Other recommendations from this report
4 more, of which 4 are open in the publisher's file.
- We recommend that the State agency bill for and collect from manufacturers rebates for single-source and top-20 multiple-source pharmacy and physician-administered drugs and refund to the…HHS OIG 19-A-02-144.01 · issued Aug 30, 2019Open Unimplemented
- We recommend that the State agency strengthen its NDC edit (implemented on January 1, 2015), to ensure that NDCs are captured for all drug utilization data.HHS OIG 19-A-02-144.03 · issued Aug 30, 2019Open Unimplemented
- We recommend that the State agency develop and implement written policies and procedures for its drug rebate program.HHS OIG 19-A-02-144.04 · issued Aug 30, 2019Open Unimplemented
- We recommend that the State agency ensure that all pharmacy and physician-administered drugs eligible for rebates are processed for rebates.HHS OIG 19-A-02-144.05 · issued Aug 30, 2019Open Unimplemented
Source
Open this report in HHS OIG's tracker This publisher's records (CSV)
Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows,
SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.